Insider Transactions in Q1 2024 at Intuitive Surgical Inc (ISRG)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 15
2024
|
Fredrik Widman VP Corporate Controller |
SELL
Open market or private sale
|
Direct |
5,041
-88.91%
|
$2,001,277
$397.07 P/Share
|
|
Mar 15
2024
|
Fredrik Widman VP Corporate Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
1,224
+45.88%
|
$72,216
$59.23 P/Share
|
|
Mar 11
2024
|
Robert De Santis EVP & Chief Strategy & Corp Op |
SELL
Open market or private sale
|
Direct |
329
-1.95%
|
$128,310
$390.16 P/Share
|
|
Mar 11
2024
|
Robert De Santis EVP & Chief Strategy & Corp Op |
BUY
Exercise of conversion of derivative security
|
Direct |
329
+1.91%
|
$77,973
$237.92 P/Share
|
|
Mar 11
2024
|
Mark Brosius SVP & Chief Mfg and Supply Cha |
SELL
Open market or private sale
|
Direct |
196
-15.63%
|
$76,440
$390.16 P/Share
|
|
Mar 08
2024
|
Robert De Santis EVP & Chief Strategy & Corp Op |
SELL
Open market or private sale
|
Direct |
20,296
-14.54%
|
$7,976,328
$393.8 P/Share
|
|
Mar 08
2024
|
Robert De Santis EVP & Chief Strategy & Corp Op |
BUY
Exercise of conversion of derivative security
|
Direct |
14,728
+9.44%
|
$3,637,816
$247.37 P/Share
|
|
Mar 08
2024
|
Mark Brosius SVP & Chief Mfg and Supply Cha |
SELL
Open market or private sale
|
Direct |
196
-13.52%
|
$76,832
$392.02 P/Share
|
|
Mar 07
2024
|
Mark Brosius SVP & Chief Mfg and Supply Cha |
SELL
Open market or private sale
|
Direct |
196
-11.91%
|
$77,028
$393.3 P/Share
|
|
Mar 06
2024
|
Mark Brosius SVP & Chief Mfg and Supply Cha |
SELL
Open market or private sale
|
Direct |
196
-10.64%
|
$75,656
$386.76 P/Share
|
|
Mar 05
2024
|
Mark Brosius SVP & Chief Mfg and Supply Cha |
SELL
Open market or private sale
|
Direct |
196
-9.62%
|
$78,400
$400.0 P/Share
|
|
Mar 01
2024
|
Myriam Curet EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,605
-84.34%
|
$614,715
$383.48 P/Share
|
|
Feb 29
2024
|
Gary S Guthart CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,230
-9.91%
|
$1,246,780
$386.59 P/Share
|
|
Feb 29
2024
|
Gary S Guthart CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,370
+16.23%
|
-
|
|
Feb 29
2024
|
Jamie Samath Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
987
-5.45%
|
$380,982
$386.59 P/Share
|
|
Feb 29
2024
|
Jamie Samath Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,006
+9.92%
|
-
|
|
Feb 29
2024
|
Mark Brosius SVP & Chief Mfg and Supply Cha |
SELL
Payment of exercise price or tax liability
|
Direct |
935
-20.65%
|
$360,910
$386.59 P/Share
|
|
Feb 29
2024
|
Mark Brosius SVP & Chief Mfg and Supply Cha |
BUY
Exercise of conversion of derivative security
|
Direct |
1,843
+28.82%
|
-
|
|
Feb 29
2024
|
Brian Edward Miller EVP & Chief Digital Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,428
-5.69%
|
$551,208
$386.59 P/Share
|
|
Feb 29
2024
|
Brian Edward Miller EVP & Chief Digital Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,817
+10.06%
|
-
|
|
Feb 29
2024
|
Marshall Mohr Executive VP Global Business S |
SELL
Payment of exercise price or tax liability
|
Direct |
1,651
-1.65%
|
$637,286
$386.59 P/Share
|
|
Feb 29
2024
|
Marshall Mohr Executive VP Global Business S |
BUY
Exercise of conversion of derivative security
|
Direct |
3,256
+3.13%
|
-
|
|
Feb 29
2024
|
Henry L Charlton SVP & Chief Commercial and Mkt |
SELL
Payment of exercise price or tax liability
|
Direct |
980
-2.06%
|
$378,280
$386.59 P/Share
|
|
Feb 29
2024
|
Henry L Charlton SVP & Chief Commercial and Mkt |
BUY
Exercise of conversion of derivative security
|
Direct |
2,201
+4.41%
|
-
|
|
Feb 29
2024
|
Robert De Santis EVP & Chief Strategy & Corp Op |
SELL
Payment of exercise price or tax liability
|
Direct |
1,700
-7.41%
|
$656,200
$386.59 P/Share
|
|
Feb 29
2024
|
Robert De Santis EVP & Chief Strategy & Corp Op |
BUY
Exercise of conversion of derivative security
|
Direct |
3,676
+13.74%
|
-
|
|
Feb 29
2024
|
Myriam Curet EVP & Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,651
-38.31%
|
$637,286
$386.59 P/Share
|
|
Feb 29
2024
|
Myriam Curet EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,256
+43.03%
|
-
|
|
Feb 29
2024
|
David J. Rosa President |
SELL
Payment of exercise price or tax liability
|
Direct |
1,905
-0.44%
|
$735,330
$386.59 P/Share
|
|
Feb 29
2024
|
David J. Rosa President |
BUY
Exercise of conversion of derivative security
|
Direct |
3,757
+0.85%
|
-
|
|
Feb 29
2024
|
Fredrik Widman VP Corporate Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
470
-5.9%
|
$181,420
$386.59 P/Share
|
|
Feb 29
2024
|
Fredrik Widman VP Corporate Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
1,317
+14.01%
|
-
|
|
Feb 28
2024
|
Marshall Mohr Executive VP Global Business S |
SELL
Open market or private sale
|
Direct |
108,790
-27.06%
|
$41,884,150
$385.08 P/Share
|
|
Feb 28
2024
|
Marshall Mohr Executive VP Global Business S |
BUY
Exercise of conversion of derivative security
|
Direct |
129,810
+23.62%
|
$19,341,690
$149.97 P/Share
|
|
Feb 27
2024
|
Myriam Curet EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
843
-73.88%
|
$325,398
$386.46 P/Share
|
|
Feb 26
2024
|
Robert De Santis EVP & Chief Strategy & Corp Op |
SELL
Payment of exercise price or tax liability
|
Direct |
498
-5.19%
|
$193,722
$389.77 P/Share
|
|
Feb 26
2024
|
Robert De Santis EVP & Chief Strategy & Corp Op |
BUY
Exercise of conversion of derivative security
|
Direct |
1,587
+14.19%
|
-
|
|
Feb 26
2024
|
Mark Brosius SVP & Chief Mfg and Supply Cha |
SELL
Payment of exercise price or tax liability
|
Direct |
434
-27.75%
|
$168,826
$389.77 P/Share
|
|
Feb 26
2024
|
Mark Brosius SVP & Chief Mfg and Supply Cha |
BUY
Exercise of conversion of derivative security
|
Direct |
855
+35.35%
|
-
|
|
Feb 26
2024
|
Myriam Curet EVP & Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
867
-43.18%
|
$337,263
$389.77 P/Share
|
|
Feb 26
2024
|
Myriam Curet EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,710
+45.99%
|
-
|
|
Feb 26
2024
|
Brian Edward Miller EVP & Chief Digital Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
649
-5.68%
|
$252,461
$389.77 P/Share
|
|
Feb 26
2024
|
Brian Edward Miller EVP & Chief Digital Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,650
+12.61%
|
-
|
|
Feb 26
2024
|
Marshall Mohr Executive VP Global Business S |
SELL
Payment of exercise price or tax liability
|
Direct |
867
-3.13%
|
$337,263
$389.77 P/Share
|
|
Feb 26
2024
|
Marshall Mohr Executive VP Global Business S |
BUY
Exercise of conversion of derivative security
|
Direct |
1,710
+5.81%
|
-
|
|
Feb 26
2024
|
Jamie Samath Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
459
-5.6%
|
$178,551
$389.77 P/Share
|
|
Feb 26
2024
|
Jamie Samath Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,284
+13.54%
|
-
|
|
Feb 26
2024
|
David J. Rosa President |
SELL
Payment of exercise price or tax liability
|
Direct |
867
-0.4%
|
$337,263
$389.77 P/Share
|
|
Feb 26
2024
|
David J. Rosa President |
BUY
Exercise of conversion of derivative security
|
Direct |
1,710
+0.78%
|
-
|
|
Feb 26
2024
|
Fredrik Widman VP Corporate Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
218
-6.61%
|
$84,802
$389.77 P/Share
|